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Abstract
Flavonoids are the active components of Herba epimedii (HEP), a commonly used herb for the management of osteoporosis in China over
the centuries. The present study aims to characterise the in vivo effects of its total flavonoid (TF) fraction on bone properties and mineral
metabolism as well as to study the mechanism involved in achieving its protective effects against ovariectomy (OVX)-induced bone loss. TF
suppressed OVX-induced increase in urinary Ca excretion as well as loss of bone mass and strength at the distal femur in mice in a dose-
dependent manner. The changes in urinary Ca excretion were inversely correlated with the expressions of renal Ca transport protein
(CaBP-28K) and vitamin D receptor mRNA in OVX mice. TF (100mg/g) treatment prevented the deterioration of trabecular bone micro-
architecture induced by OVX in mice. In addition, TF treatment increased the expression of type I collagen and osteocalcin mRNA and
the ratio of osteoprotegerin/receptor activator of NF-kB ligand mRNA, and suppressed the increase in IL-6 mRNA induced by OVX in
the femur of mice. The present results indicate that the optimal dosage of the TF fraction of HEP for the improvement of bone properties
and mineral metabolism in OVX mice was between 50 and 100mg/g. Mechanistic studies indicated that TF might increase renal Ca reab-
sorption, stimulate the process of osteoblast formation as well as suppress the process of osteoclastogenesis in OVX mice.
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The Women’s Health Initiative as well as the Million
Women Study indicated that oestrogen or hormone repla-
cement therapy increased the risk of postmenopausal
women to develop breast cancer, stroke, thrombosis and
CVD(1–3). These findings have led to the advice that hor-
mone replacement therapy should not be considered
first-line therapy for the prevention of osteoporosis. As
existing therapeutic agents, such as bisphosphonates,
selective oestrogen receptor modulators, teriparatide and
calcitonin(4), are either of high cost or associated with
different side effects, alternative approaches for the pre-
vention or treatment of osteoporosis are worth exploring.
Herba epimedii (HEP) is commonly used in traditional
Chinese medicine for ‘strengthening the kidney’(5,6) and
nourishes the bone. HEP is one of the most frequently pre-
scribed herbs in traditional Chinese medicine formula for
the management of osteoporosis in China. Studies have
shown that HEP extract could reduce bone loss in an ovari-
ectomised (OVX) rat model(7–11) as well as promote cell
proliferation and increase alkaline phosphatase activity in
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primary rat calvarial osteoblasts(12–18). A recent study also
demonstrated that it can promote the osteogenic differen-
tiation of human bone marrow-derived mesenchymal
stem cells(19). Our previous study indicated that HEP total
extract could increase trabecular bone mineral density
(BMD) in ovariectomised rats and stimulate osteoblastic
cell proliferation and differentiation in UMR 106 cells.
HEP total extract could also induce the expression of
osteoprotegerin (OPG, a soluble, decoy receptor that
binds receptor activator of NF-kB ligand (RANKL) mRNA
expression) and the ratio of OPG to RANKL (a mem-
brane-bound TNF ligand family) expression in UMR 106
cells, suggesting that it could modulate the process of
osteoclastogenesis(20).
A recent study by Zhang et al.(21) demonstrated that a
preparation containing 60 mg icariin (the major flavonoid
compound in HEP), 15 mg daidzein and 3 mg genistein
could reduce bone loss in late postmenopausal women
in a 24-month randomised, double-blind and placebo-
controlled trial. This study provides evidence to support
that the flavonoid compounds in HEP might account for
the bone-protective effects of HEP in vivo. Furthermore,
numerous in vitro (22–24) and in vivo (25 ) studies showed
that icariin could stimulate osteoblastic cell functions, sup-
press osteoclastic activities and improve bone mineral den-
sity and bone strength in ovariectomised rats. Our recent
study further suggests that the anabolic effects of icariin
on bone might be mediated through ligand-independent
activation of oestrogen receptor(24). These studies further
indicate that flavonoid compounds are the active com-
ponents in HEP extract, which account for its bone-protec-
tive effects in vivo. However, the optimal dosage and the
mechanism of actions by which flavonoid compounds in
HEP exert bone-protective effects in vivo are not clear.
In the present study, we aim to characterise the dose-
dependent effects of the total flavonoid (TF) fraction of
HEP extract on bone and mineral metabolism in ovari-
ectomised mice as well as to elucidate the mechanism of
actions involved in mediating its bone-protective effects
in vivo.
Materials and methods
Preparation of total flavonoids fraction from Herba
epimedii total extract
HEP (E. Koreanum Nakai) was collected in June 2003–July
2003 in a valley in Xinbin, Liaoning Province, and authenti-
cated by Q.S. Sun, Professor of Pharmacognosy, Shenyang
Pharmaceutical University, China. A voucher specimen (no.
19980816) has been deposited in the Institute of Traditional
Chinese Medicine and Natural Products of Jinan University,
China. The total extract was subjected to water extraction
and column chromatography to yield four fractions with
different polarities, namely water, 30 %, 50 % and 95 %
ethanol. The fractions of 50 and 95 % ethanol were
pooled to give the TF fraction. The preparation was filtered
and concentrated under vacuum to produce a powder at a
yield of 9·5 %. The TF fraction was stored at room tempera-
ture before use. Fig. 1 shows a typical chromatographic
profile of the TF fraction of the HEP total extract. HPLC
analysis has been performed with standard compounds
using the same elution procedure as that used with the
TF extract of HEP. Peaks in the profile of TF with the
same retention time with authentic markers (epimedin B,
icariin, caohuoside E and baohuoside I) were identified.
Animals
Experimental protocols and procedures were approved by
the Institutional Animal Care and Use Committee of The
Hong Kong Polytechnic University. Female C57BL/6J
mice were purchased from the Laboratory Animal Services
Centre (the Chinese University of Hong Kong, HK).
Expt 1: dose-dependent effects of total flavonoids fraction
of Herba epimedii extract in ovariectomised mice
Experimental groupings. One-month-old C57BL/6J mice
were randomly separated into seven groups including
Sham þ vehicle (Sham, n 8), OVX þ vehicle (OVX, n 8),
OVX þ 17b-oestradiol (E2, 4mg/g per d, n 8), OVX þ TF
(TF50, 50mg/g per d, n 8), OVX þ TF (TF100, 100mg/g
per d, n 8), OVX þ TF (TF200, 200mg/g per d, n 8) and
OVX þ TF (TF400, 400mg/g per d, n 8). The animals
were either ovariectomised or sham operated. After recov-
ery from surgery for 18 d, they were orally administered
with vehicle, E2 or TF for 6 weeks. The animals were fed
with diet containing 0·6 % Ca and 0·65 % P (TD 98 005;
Teklad, Madison, WI, USA) throughout the course of the
studies. During the study, mice were pair-fed and body
weight was recorded weekly. All the mice had free
access to distilled water and were fed 3 g/d per mice of
the respective diet, the minimum average food intake
of the mice during the acclimatisation period. Before kill-
ing, the mice were housed individually in a metabolism
cage for the collection of urine. On the day of killing,
blood was collected from the orbital venous sinus of the
mice. The uterus was collected, and the uterine index or
uterus/body weight ratio was calculated by normalising
the weight of the uterus with the final body weight of
the mice. Kidneys were collected for mRNA expression
detection. The bone specimens were obtained for periph-
eral computed tomography analysis.
Biochemical assays of serum and urine samples. Ca
and inorganic P concentrations in serum and urine were
determined by an o-cresolphthalein complexone method
and a p-methylaminophenol reduction method, respect-
ively, using commercial kits (Wako Pure Chemical
Industries Limited, Osaka, Japan). Urinary Ca and P con-
centrations were normalised with creatinine concentration
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and were expressed as urinary Ca to creatinine ratio and
urinary P to creatinine ratio, respectively.
Bone mineral density analysis by peripheral quantitative
computed tomography. Peripheral quantitative computed
tomography scanning was performed using XCT-2000
(StraTec Medizintechnik GmbH, Durlacher, Germany).
Femurs were placed on a plastic holder and oriented at
the centre of the scanning area. The long axis of diaphysis
was adjusted parallel to the scanning direction. At a
distance of 1·5 mm away from the apex of femur, proximal
and distal ends were scanned at a voxel size of 0·3 mm2.
BMD (in mg/cm3) and polar stress–strain index
(polar-SSI) (in mm3) of femur were measured. SSI is an
index for the estimation of torsional bone strength(26).
RNA isolation from kidney and quantitative real-time
RT-PCR. Whole kidney was harvested and immediately
frozen in liquid N2 and stored at 2808C. Frozen kidney
was thawed in Trizol reagent and homogenised. Total
RNA was isolated from kidney using Trizol according to
the manufacturer’s protocol. Total RNA was reverse tran-
scribed using the High-Capacity complementary DNA
Reverse Transcription Kit (Applied Biosystems, Inc.,
Foster City, CA, USA) at 258C for 10 min, 378C for 2 h and
858C for 5 s. The sequences of the PCR primers were
50-TCCACGATGGATCTGAATGA-30 (vitamin D receptor
(VDR) forward) and 50-GCAGCACATGRRCTTCCTCA-30
(VDR reverse) for VDR, 50-ATGCCAGCAACTGAAGTCCT-30
(CaBP-28K forward) and 50-AGCAAAGCATCCAGCTCATT-
30 (CaBP-28K reverse) for CaBP-28K, and 50-GACCACAGT-
CCATGCCATCAC-30 (glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) forward) and 50-GCTGTTGAAGTCG-
CAGGAGAC-30 (GAPDH reverse) for the housekeeping
gene GAPDH. PCR was carried out in 20ml reaction
mixture containing 10ml iQe SYBR Green Supermix
(Bio-Rad Laboratories, Hercules, CA, USA) and 0·5ml of
complementary DNA template using an ABI 7900HT Fast
Real-Time PCR system (Applied Biosystems, Inc.). The
following cycle parameters were used: one cycle of 958C
for 1 min and forty cycles of 958C for 20 s; different melting
temperature for 20 s and 728C for 18 s. Upon completion,
a melting curve was examined. Standard curves were
generated using serially diluted solutions of complemen-
tary DNA derived from control sample. The target gene
transcripts in each sample were normalised on the basis
of its GAPDH.
Expt 2: bone anabolic effect of total flavonoid at optimal
dosage in ovariectomised mice
Experimental groupings. Based on the results of Expt 1,
the optimised dosage of TF (100mg/g per d) for increasing
total BMD and polar SSI at distal femur as well as renal
CaBP-28K and VDR mRNA expression was chosen for the
second study. One-month-old C57BL/6J mice were ran-
domly separated into four groups including Sham þ
vehicle (Sham, n 8), OVX þ vehicle (n 8), OVX þ E2 (n 8)
and OVX þ TF (TF100, 100mg/g per d, n 8). After recovery
from surgery for 18 d, they were orally administered with
nAU
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Fig. 1. Reverse-phase HPLC for the qualitative analysis of the total flavonoid extract of Herbal epimedii (HEP). Icariin, epimedin B, caohuoside E and baohuoside
I are the main active compounds in HEP according to the Chinese Pharmacopoeia. HPLC analysis has been performed with standard compounds using the same
elution procedure as that used with the total flavonoid (TF) extract of HEP. The peaks in the profile of TF with the same retention time with authentic markers
were identified and used for confirmation of the identity of the TF extract HEP.
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vehicle, E2 (4mg/g per d) and TF (100mg/g per d) for
6 weeks.
Bone microarchitecture analysis by microCT. Right
femurs from mice were scanned using the microCT
system (viva-CT40; Scanco Medical, Bassersdorf, Switzer-
land) to evaluate trabecular bone volume fraction and
microarchitecture in the epiphysis region of the femur
end. The scanning position of distal femur was initiated
at the distal end of the femur. All scans were done in
21mm sections to a total of 100 slices per scan. Raw data
generated were reconstructed to the image files. The
two-dimensional and three-dimensional evaluation can
be generated by the Scanco compiler in the Virtual
Memory System. Different threshold values were chosen
for binarising the trabecular and cortical bones, and the
volume of interest was contoured in twenty serial slices
in 100 scanned slices for evaluation. The trabecular and
the cortical parts of the distal femur were separated with
semi-automatically drawing contours. Only trabecular
bones were contoured, and the threshold value is set as
210 mg hydroxyapatite/cm3. After evaluations, five micro-
structural parameters were used in the data analysis such
as bone volume/tissue volume, trabecular number, trabe-
cular thickness, trabecular separation and structural
model index.
RNA isolation from bone and quantitative real-time
RT-PCR. Whole left femur was harvested and immediately
frozen in liquid N2 and stored at 2808C. Frozen femur
was put in an RNase-free mortar and pestle which con-
tained liquid N2, and then grinded into a fine pieces
immersed in liquid N2. Then, the frozen powders were
transferred into a tube containing Trizol. Total RNA was
extracted, and the gene expression of OPG, RANKL, type
I collagen, osteocalcin, IL-6 and GAPDH was assessed as
described in Expt 1. The sequences of the PCR primers
were 50-TGAGTGTGAGGAAGGGCGTTA-30 (OPG forward)
and 50-CCATCTGGACATTTTTTGCAAA-30 (OPG reverse),
50-GCACACCTCACCATCAATGCT-30 (RANKL forward)
and 50-GGTACCAAGAGGACAGAGTGACTTTA-30 (RANKL
reverse), 50-CTTGGTGGTTTTGTATTCGATGAC-30 (type I
collagen forward) and 50-GCGAAGGCAACAGTCGCT-30
(type I collagen reverse), 50-CTCACAGATGCCAAGCCCA-
30 (osteocalcin forward) and 50-CCAAGGTAGCGCCGGA-
GTCT-30 (osteocalcin reverse), 50-TGGGAAATCGTGGAAA-
TGAGA-30 (IL-6 forward) and 50-CAAGTGCATCATCGTTG-
TTCATAC-30 (IL-6 reverse), and 50-GACCACAGTCCATGCC-
ATCAC-30 (GAPDH forward) and 50-GCTGTTGAAGTCGC-
AGGAGAC-30 (GAPDH reverse), respectively.
Statistical analysis
The data were analysed by one-way ANOVA, and followed
by Tukey’s multiple comparison test as a post test to com-
pare the group means if overall P,0·05. GraphPad Prism
(El Camino Real, CA, USA) version 4.4 software was used.
The results were reported as means with their standard Ta
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errors. A P-value , 0·05 was considered statistically
significant.
Results
Dose-dependent effects of total flavonoid on body weight,
uterine index and biochemical parameters in
ovariectomised mice
Body weight increased significantly in the OVX group and
50mg/g TF group. Oestradiol, but not TF, prevented the
OVX-induced increase in weight gain in mice (Table 1).
The uterine index was significantly reduced in OVX
mice, suggesting that the surgery was successful. In con-
trast to E2, TF did not increase the uterus index in OVX
mice (Table 1). Serum Ca levels were not significantly
altered by ovariectomy or treatment with E2, or 50 and
100mg/g TF; while 200 and 400mg/g TF decreased serum
Ca levels in OVX mice (v. OVX, P,0·05). Urinary Ca
excretion was suppressed in OVX mice treated with E2
and TF at 50mg/g (v. OVX, P,0·05 and 0·01, respectively).
The suppression of urinary Ca excretion by TF in OVX
mice was found to be dose dependent. There were no stat-
istically significant differences in serum P level and urinary
P excretion between each group.
Dose-dependent effects of total flavonoid on bone mineral
density and bone strength in femur of ovariectomised mice
The effects of OVX, E2 and TF on bone mass and SSI at
distal femur are presented in Table 2. Ovariectomy
decreased total BMD (211 %), trabecular BMD (213 %)
and polar SSI (253 %) at distal femur in mice. Treatment
of OVX mice with E2 significantly increased total BMD, tra-
becular BMD as well as polar SSI at distal femur by 40 %
(P,0·001), 56 % (P,0·001) and 228 % (P,0·001), respect-
ively, when compared with OVX mice. TF increased total
BMD, and the most effective dosages were 50 and
100mg/g (v. OVX), but the increase did not reach statistical
significance. TF also increased the trabecular BMD with the
most effective dosage at 50mg/g (v. OVX, P,0·05). Treat-
ment of OVX mice with TF (50 and 100mg/g) dramatically
increased polar SSI at the distal femur by 119 % (P,0·001)
and 131 % (P,0·001), respectively.
Dose-dependent effects of total flavonoid on vitamin D
receptor and calcium transport protein mRNA expression
in kidney
1,25-Dihydroxyvitamin D3 regulates Ca absorption through
acting on the epithelial Ca-transporting proteins primarily
via a genomic action after binding with its receptor
(VDR). CaBP-28K is the major vitamin D-dependent
CaBP-28K expressed in the kidney(27). To determine
whether the suppression of urinary Ca excretion by TF
was associated with the changes in renal expression of
major proteins involved in renal Ca transport, renal
expression of CaBP-28K and VDR mRNA was determined.
As shown in Fig. 2, ovariectomy did not alter renal
expression of CaBP-28K and VDR mRNA in mice. E2 signifi-
cantly increased renal VDR mRNA, but not CaBP-28K
expression, in OVX mice (v. OVX, P,0·05). TF increased
CaBP-28K and VDR mRNA expression in OVX mice, and
the maximal effect was at 100 and 50mg/g, respectively.
Effects of total flavonoid on bone microarchitecture at
distal femur in ovariectomised mice analysed by microCT
The present results showed that the maximal bone-protec-
tive effects on total BMD, trabecular BMD as well as polar
SSI were between 50 and 100mg/g of TF of HEP, and the
optimal stimulating effect on renal CaBP-28K and VDR
mRNA expression was also between 50 and 100mg/g of
TF. Based on these results, 100mg/g of TF was chosen
for subsequent experiments. The bone-protective effects
of E2 and TF on bone microarchitecture at distal femur of
OVX mice were clearly illustrated by their three-dimen-
sional images obtained from microCT analysis as shown
in Fig. 3(a). Ovariectomy significantly decreased bone
Table 2. Effects of 6-week treatment of 17b-oestradiol (E2) and total flavonoids (TF) on bone mineral density and bone strength at distal femur
in ovariectomised mice analysed by peripheral quantitative computed tomography*
(Mean values with their standard errors, n 6–8 animals)
Total BMD (mg/ccm) Trabecular BMD (mg/ccm) Polar SSI (mm3)
Mean SEM P Mean SEM P Mean SEM P
Sham 388·6 12·3 391·3 14·4 0·68 0·05
OVX 347·3 9·6 342·6 8·3 ,0·05† 0·32 0·05 ,0·01††
E2 489·4 9·6 ,0·001†††
, 0·001‡‡‡
536·1 10·9 ,0·001†††
,0·001‡‡‡
1·05 0·06 ,0·001†††
, 0·001‡‡‡
TF50 (50mg/g) 387·7 9·5 396·4 11·5 ,0·05‡ 0·70 0·07 ,0·001‡‡‡
TF100 (100mg/g) 387·1 10·0 384·1 11·3 0·74 0·06 ,0·001‡‡‡
TF200 (200mg/g) 371·0 6·0 376·3 6·2 0·60 0·03
TF400 (400mg/g) 367·1 7·6 364·2 7·4 0·54 0·06
BMD, bone mineral density; SSI, stress–strain index; OVX, ovariectomy.
Mean values were significantly different when compared with that of the Sham group: †P,0·05, ††P,0·01, †††P,0·001.
Mean values were significantly different when compared with that of the OVX group: ‡P,0·05, ‡‡‡P,0·001.
* The data were analysed by one-way ANOVA and followed by Tukey’s multiple comparison test.
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volume/tissue volume, trabecular number, and trabecular
thickness, and increased trabecular separation and struc-
tural model index when compared to the sham group.
Treatment with E2 and TF significantly prevented the
reduction in bone volume/tissue volume, trabecular
number, and trabecular thickness as well as the increase
in trabecular separation and structural model index in
OVX mice (Fig. 3(b)–(f)).
Effects of total flavonoid on type I collagen, osteocalcin,
osteoprotegerin, receptor activator of NF-kB ligand and
IL-6 gene expressions in femur
OVX appeared to decrease the expression of type I
collagen (Fig. 4(a)) and osteocalcin (Fig. 4(b)) mRNA in
the femur of mice, but the decrease was NS. E2 and TF
significantly increased type I collagen and osteocalcin
mRNA expressions in the femur of OVX mice (Fig. 4(a)
and (b)). Treatment of OVX mice with E2 significantly
decreased RANKL mRNA expression (Fig. 4(d)), but did
not significantly affect OPG mRNA expression (Fig. 4(c))
in femur. Both E2 and TF significantly increased the ratio
of OPG/RANKL in the femur of OVX mice (Fig. 4(e)),
suggesting that they might modulate the process of osteo-
clastogenesis via their actions on OPG and RANKL
expression in bone cells. OVX significantly increased the
gene expression of IL-6 (P,0·01). TF, but not E2, treatment
significantly decreased the IL-6 gene expression in the
femur of OVX mice (P,0·05).
Discussion
The present study clearly demonstrated that the TF of HEP
could suppress OVX-induced increase in urinary Ca
excretion as well as loss in bone mass and bone strength
in mice in a dose-dependent manner. In addition, renal
expressions of CaBP-28K and VDR mRNA were dose
dependently induced by treatment with TF in OVX mice.
Furthermore, TF could improve trabecular microarchitec-
ture in OVX mice, and significantly increased the mRNA
expression of type I collagen, osteocalcin and OPG/
RANKL ratio and suppressed IL-6 mRNA expression in
the femur of OVX mice.
The present study demonstrated that the effects of TF on
bone mass in OVX mice were dose dependent. It increased
total BMD and trabecular BMD of the distal femur in OVX
mice with the most effective dosages between 50 and
100mg/g. Moreover, the present study demonstrated that
the effects of TF on torsional bone strength (polar SSI) at
distal femur in OVX mice were also dose dependent, and
the most effective doses were also between 50 and
100mg/g. It was of interest to note that higher concen-
tration of TF (200 and 400mg/g) did not result in further
increase in bone mass and torsional bone strength at the
distal femur in OVX mice.
Oestrogen plays an important role in Ca2þ homoeostasis,
and oestrogen deficiency results in a negative Ca2þ balance
and bone loss in postmenopausal women(28,29). Ovari-
ectomy induced a significant increase in urinary Ca level,
and this effect could be reversed by TF. The present results
indicated that the suppression of urinary Ca excretion by
TF was negatively associated with the increase in renal
expressions of CaBP-28K and VDR mRNA in OVX mice.
The most effective dosages for their expressions in
kidney were 100 and 50mg/g, respectively. As CaBP-28K
is a vitamin D-dependent CaBP-28K in the kidney, it is
possible that the decrease in urinary Ca loss by TF in
OVX mice might be in part mediated through an increase
in renal Ca transport via the induction of CaBP-28K
expression. In addition, the induction of VDR expression
in kidney by TF in OVX mice might increase renal
responsiveness to vitamin D, thereby increasing vitamin
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Fig. 2. Effects of 17b-oestradiol (E2) and total flavonoid (TF) on Ca transport
protein (CaBP-28K) and vitamin D receptor (VDR) mRNA expressions in
kidney. Ovariectomy (OVX) mice were treated with vehicle (Sham or OVX), E2
(4mg/g per d) or four doses of TF (TF50, 50mg/g per d; TF100, 100mg/g per d;
TF200, 200mg/g per d and TF400, 400mg/g per d) for 6 weeks. At killing, kidney
was collected and total RNA was isolated. Real-time RT-PCR was performed to
determine the mRNA expressions of (a) CaBP-28K and (b) VDR, which were
normalised with that of glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
The data were obtained at 6 weeks and were expressed as a percentage of the
control mice treated with vehicle. Results were expressed as means with their
standard errors. Mean values were significantly different when compared with
that of the sham group: *P,0·05, **P,0·01, ***P,0·001. Mean values
were significantly different when compared with that of the OVX group (n 5–6):
† P,0·05, †† P,0·01.
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Fig. 3. Effects of 17b-oestradiol (E2) and total flavonoid (TF) on bone microarchitecture at distal femur in ovariectomised mice analysed by microCT. Ovariectomy (OVX)
mice were treated with vehicle (Sham or OVX), E2 (4mg/g per d) or TF (100mg/g per d) for 6 weeks. (a) Representative 3D microCT images of distal femur. Graphical
measurement of bone volume/tissue volume (BV/TV) (b), trabecular number (Tb.N) (c), trabecular thickness (Tb.Th) (d), separation (Tb.Sp) (e) and structural model index
(SMI) (f) as determined from the microCT. Results were expressed as means with their standard errors. Mean values were significantly different when compared with that
of the Sham group: *P,0·05, **P,0·01, ***P,0·001. Mean values were significantly different when compared with that of the OVX group (n 8): †P,0·05, †††P,0·001.
W.-F. Chen et al.186
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
D-dependent expression of CaBP-28K in kidneys. Further
study will be needed to confirm whether TF will increase
renal Ca transport in OVX mice. Nonetheless, the present
study indicated that TF not only exerts protective effects
in bone tissues but also exerts additional effects on the
mRNA expression of CaBP-28K in kidney, which lead to
the conservation of bone mass in OVX mice.
Ovariectomy produced apparent deterioration of trabe-
cular three-dimensional microarchitecture in mice. The
present study showed that TF treatment prevented OVX-
induced deterioration of microstructural parameters at the
distal femur in mice. Specifically, TF at 100mg/g per d
could restore the loss of bone volume/tissue volume,
trabecular number and trabecular thickness while
suppressing the increase in trabecular separation and struc-
tural modulus index at distal femur in OVX mice. These
results indicated that TF was effective not only in preser-
ving bone mass but also in preventing the deterioration
of bone microarchitecture associated with oestrogen
deficiency in mice.
The study of the changes in femur gene expression in
response to TF provides insights to understand its mechan-
ism of actions involved in improvement of bone quality in
OVX mice. Type I collagen and osteocalcin are the most
abundant extracellular proteins produced by osteoblasts
in bone and are essential for maintaining bone
strength(30,31). TF could significantly increase type I col-
lagen and osteocalcin mRNA expression in femur of OVX
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Fig. 4. Effects of 17b-oestradiol (E2) and total flavonoid (TF) on type I collagen, osteocalcin, osteoprotegerin (OPG), receptor activator of NF-kB ligand (RANKL)
and IL-6 mRNA expressions in femur. Ovariectomy (OVX) mice were treated with vehicle (Sham or OVX), E2 (4mg/g per d) or TF (100mg/g per d) for 6 weeks.
At killing, femurs were collected and total RNA was isolated. Real-time RT-PCR was performed to determine the mRNA expressions of type I collagen (a), osteo-
calcin (b), OPG (c), RANKL (d), OPG/RANKL (e) and IL-6 (f), which were normalised with that of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The data
were obtained at 6 weeks and were expressed as a percentage of the control mice treated with vehicle. Results were expressed as means with their standard
errors. Mean values were significantly different when compared with that of the Sham group: **P,0·01. Mean values were significantly different when compared
with that of the OVX group (n 5–8): †P,0·05, ††P,0·01, †††P,0·001.
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mice to a level comparable with those treated with oestra-
diol. These in vivo results are in agreement with previous
reports by us(20) and others(15–19) that HEP could enhance
bone formation through its action on cells in the osteoblas-
tic lineage. The equilibrium of OPG and RANKL expression
plays an important role in controlling bone remodelling(32).
The secretion of OPG by osteoblastic cells could block the
interaction of RANKL with its functional receptor RANK
expressed on the osteoclastic cell surface, thereby inhibit-
ing osteoclastogenesis. The present results revealed that
both oestradiol and TF increase the ratio of OPG/RANKL
mRNA expression in the femur of OVX mice, suggesting
that both agents can inhibit the process of osteoclastogen-
esis in vivo. However, the mechanism by which TF modu-
lates osteoclastogenesis might be different from that of
oestradiol. The results indicated that the increase in the
OPG/RANKL ratio by TF was due to its inductive effects
on OPG mRNA expression, while the increase by oestra-
diol was due to its suppressive effect on RANKL mRNA
expression in vivo.
IL-6 is known to be a potent stimulator of bone resorp-
tion, and plays an important role in the induction of osteo-
clastogenesis and bone loss upon oestrogen
depletion(33,34). The present results indicated that IL-6
mRNA in the femur of mice appeared to be significantly
increased with ovariectomy and decreased with TF treat-
ment in OVX mice. These results were in agreement with
those reported previously by Wang et al.(8) in which HEP
increased IL-6 mRNA in bone of OVX rats. Thus, TF
might suppress the process of osteoclastogenesis not only
via the induction of the OPG/RANKL ratio but also via
the inhibition of the OVX-induced increase in levels of
IL-6 in bone.
In search for safe and effective alternatives for treatment
of postmenopausal osteoporosis, HEP has received much
attention in recent years to demonstrate its efficacy as
well as mechanism of actions(7–19,22–24). In the present
study, we have demonstrated that the optimal dosage of
TF for improving bone mass and bone strength as well
as for decreasing urinary Ca excretion in OVX mice was
between 50 and 100mg/g per d. The present results
showed that a further increase in the dosages of TF
would compromise its positive effects on bone mass as
well as its suppressive effects on urinary Ca excretion.
The optimal dosages reported in the present study were
in agreement with the dosages used in other reported
studies using OVX rats as a model(12–14). For example,
the study by Songlin et al.(14) showed that treatment of
11-month-old OVX rats with a flavonoid fraction of HEP
at 10 mg/kg per d for 12 weeks increased BMD as well
as improved bone microarchitecture. The dosage used in
their studies is close to the optimal dosages reported in
the present study, in which the equivalent dose in rats
will be 25–50 mg/kg per d or mg/g per d. Furthermore,
the present study was the first to report that TF also
exerts additional effects on the mRNA expression of
CaBP-28K in kidney, which potentially led to the suppres-
sion of urinary Ca excretion and the conservation of bone
mass in OVX mice.
The present study clearly demonstrated that the TF of
HEP could protect against bone loss and bone deterio-
ration associated with oestrogen deficiency without exert-
ing uterotrophic effects. Gene expression studies
indicated that TF treatment achieves its osteoprotective
actions in vivo via the modulation of renal Ca transport,
osteoblastic functions, the process of osteoclastogenesis
as well as osteoclastic functions in OVX mice. The present
study showed that TF is the active fraction in HEP and
defines the optimal dosages of HEP for achieving bone-
protective actions in vivo.
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